Profile data is unavailable for this security.
About the company
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
- Revenue in MXN (TTM)18.82bn
- Net income in MXN2.22bn
- Incorporated1996
- Employees1.62k
- LocationGenomma Lab Internacional SAB de CVEdificio SamaraAntonio Dovali Jaime no. 70 Piso 2Colonia Santa FeALVARO OBREGON 01210MexicoMEX
- Phone+52 5 550810000
- Fax+52 5 550810000
- Websitehttps://www.genommalab.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kexing Biopharm Co Ltd | 3.67bn | 117.20m | 20.12bn | 947.00 | 172.27 | 4.56 | -- | 5.48 | 0.2229 | 0.2229 | 7.18 | 8.42 | 0.4474 | 3.07 | 3.26 | 1,478,164.00 | 1.29 | -0.1893 | 1.76 | -0.2413 | 66.59 | 74.57 | 2.89 | -0.3956 | 1.36 | 2.43 | 0.4286 | -- | 11.75 | 3.39 | 116.54 | -27.74 | 11.90 | -- |
| Ocumension Therapeutics | 1.10bn | -704.63m | 20.38bn | 489.00 | -- | 2.06 | -- | 18.59 | -0.4322 | -0.4322 | 0.6684 | 5.07 | 0.1152 | 4.93 | 2.94 | 934,665.90 | -7.41 | -24.03 | -7.92 | -25.71 | 53.93 | 58.38 | -64.29 | -400.90 | 6.02 | -- | 0.0068 | -- | 69.38 | 365.95 | 29.36 | -- | 213.01 | -- |
| BioGaia AB | 2.82bn | 614.45m | 20.42bn | 224.00 | 34.10 | 5.94 | 31.15 | 7.25 | 3.06 | 3.06 | 14.04 | 17.59 | 0.629 | -- | -- | 6,307,498.00 | 13.73 | 14.76 | 14.90 | 16.03 | 72.81 | 73.06 | 21.83 | 27.38 | -- | -- | 0.00 | 129.54 | 9.73 | 13.11 | -3.82 | 13.40 | -18.36 | 33.95 |
| Pacira Biosciences Inc | 13.23bn | -1.95bn | 20.47bn | 790.00 | -- | 1.36 | -- | 1.55 | -2.25 | -2.25 | 15.19 | 17.25 | 0.4434 | 1.36 | 6.81 | 889,584.80 | -6.54 | 1.87 | -7.51 | 2.22 | 77.61 | 73.06 | -14.76 | 4.84 | 1.99 | -- | 0.4222 | 0.00 | 3.85 | 10.73 | -337.30 | -- | 0.9219 | -- |
| Amphastar Pharmaceuticals Inc | 13.75bn | 2.67bn | 20.48bn | 2.03k | 8.38 | 1.46 | 5.44 | 1.49 | 2.76 | 2.76 | 14.25 | 15.76 | 0.4566 | 2.40 | 5.17 | 360,285.50 | 8.85 | 9.84 | 10.31 | 11.71 | 50.50 | 49.55 | 19.38 | 17.15 | 2.02 | 10.89 | 0.4457 | 0.00 | 13.59 | 17.82 | 15.98 | 26.66 | -0.2486 | -- |
| Genomma Lab Internacional SAB de CV | 18.82bn | 2.22bn | 20.75bn | 1.62k | 9.11 | 1.82 | 8.03 | 1.10 | 2.28 | 1.72 | 19.10 | 11.39 | 0.829 | 3.28 | 3.78 | 11,723,310.00 | 9.77 | 6.85 | 14.73 | 10.26 | 63.56 | 61.94 | 11.79 | 8.93 | 1.29 | 8.14 | 0.3883 | 24.81 | 12.99 | 7.92 | 92.74 | 22.77 | 1.53 | -- |
| Beijing Foyou Pharma Co Ltd | 9.12bn | 1.28bn | 20.85bn | 3.64k | 16.16 | 2.11 | -- | 2.29 | 1.02 | 1.02 | 7.35 | 7.85 | 0.7419 | 3.56 | 10.10 | 953,181.10 | 10.45 | 12.53 | 13.48 | 17.64 | 66.24 | 68.01 | 14.09 | 13.02 | 2.44 | -- | 0.0109 | 33.16 | 3.17 | 7.28 | -0.0188 | 17.44 | 35.29 | -- |
| Liquidia Corp | 266.26m | -2.41bn | 21.08bn | 157.00 | -- | 22.48 | -- | 79.17 | -1.56 | -1.56 | 0.1743 | 0.5828 | 0.0666 | 2.44 | 7.41 | 90,089.17 | -60.22 | -58.31 | -74.73 | -66.89 | 58.08 | 75.60 | -903.80 | -564.24 | 2.91 | -17.94 | 0.7391 | -- | -19.97 | 11.64 | -66.10 | -- | 35.49 | -- |
| Harrow Inc | 4.01bn | -408.43m | 21.33bn | 382.00 | -- | 19.50 | -- | 5.32 | -0.607 | -0.607 | 5.96 | 1.58 | 0.6453 | 5.04 | 4.02 | 557,219.90 | -6.58 | -9.11 | -10.05 | -10.89 | 74.53 | 72.78 | -10.19 | -14.34 | 0.8494 | 0.1846 | 0.7974 | -- | 53.32 | 31.29 | 28.39 | -- | 92.29 | -- |
Data as of Jun 30 2025. Currency figures normalised to Genomma Lab Internacional SAB de CV's reporting currency: Mexican New Peso MXN
20.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Apr 2025 | 39.21m | 3.92% |
| The Vanguard Group, Inc.as of 04 Jun 2025 | 28.15m | 2.82% |
| BlackRock M�xico SA de CV Asesor en Inversiones Independienteas of 05 Jun 2025 | 20.76m | 2.08% |
| BlackRock Fund Advisorsas of 05 Jun 2025 | 20.02m | 2.00% |
| Swedbank Robur Fonder ABas of 30 May 2025 | 19.26m | 1.93% |
| Skagen ASas of 30 Apr 2025 | 17.93m | 1.79% |
| Lemanik Asset Management SAas of 30 Jun 2024 | 17.62m | 1.76% |
| Dimensional Fund Advisors LPas of 05 Jun 2025 | 13.95m | 1.40% |
| Wellington Management Co. LLPas of 30 Apr 2025 | 13.92m | 1.39% |
| North of South Capital LLPas of 30 Jun 2024 | 12.75m | 1.28% |
More ▼
Data from 31 Dec 2024 - 18 Jun 2025Source: FactSet Research Systems Inc.
